Navigation Links
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
Date:7/7/2008

25-4860 internationally. A telephone replay will be available following the conclusion of the call until July 9 at midnight by dialing 888-203-1112 from the U.S. or 719-457-0820 for international callers and entering passcode 4109873. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to improve the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon(TM) in Alzheimer's disease, a Phase 2 clinical trial of Dimebon in patients with Huntington's disease, and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated future development of Dimebon, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candida
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... According to a new market ... Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... 17,689.0 Million USD by 2020 at a CAGR of ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ) ... on China,s Tobramycin Market, 2010-2019" report to their ... eye drop and ointment are the most common prescription ... caused by eye infection. Currently, dozens of enterprises in ... tobramycin, among which the Top 5 are s.a. Alcon- ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... Oct. 31, 2011 Rock Creek Pharmaceuticals, a wholly owned ... today announced the second presentation of research findings related to ... a Tobacco Alkaloid, Ameliorates Disease in a Mouse Model of ... meeting of the American Thyroid Association in Indian Wells, CA ...
... SYDNEY, Oct. 31, 2011  To successfully irradiate a moving lung ... the tumor from moving or a means to compensate for ... Hospital Cancer Centre (Randwick, New South Wales) chose the second ... for the first time to treat a 75-year-old male patient ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatabloc™ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting 2Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatabloc™ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting 3Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatabloc™ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting 4Australia's Prince of Wales Hospital Launches New Era of Targeted Lung Cancer Treatments with Elekta's Advanced 4D Motion Management Technology 2Australia's Prince of Wales Hospital Launches New Era of Targeted Lung Cancer Treatments with Elekta's Advanced 4D Motion Management Technology 3
(Date:8/29/2015)... ... , ... On September 30, 2015, the Career and Transfer Center (CTC) at ... Maricopa Community Colleges , will be hosting a Job Expo to provide a professional, ... , The Expo has expanded to much more than just a typical job and ...
(Date:8/29/2015)... Raleigh, NC (PRWEB) , ... August 29, 2015 ... ... about how mesothelioma develops, may extend and improve the lives of patients, according ... its website. Click here to read the full article. , The ...
(Date:8/29/2015)... ... August 29, 2015 , ... People who have heart or ... or asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those ... heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of furthering music education ... year to the Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed ... support music education in the underfunded school districts of Mendon and its neighboring town ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... Sept. 24 The American Society of,Transplantation (AST) is ... to a unique target audience -- human resource professionals., ... of the Society of Human,Resource Management (SHRM) nationwide to ... program is designed to encourage,employers to adopt paid leave ...
... nationwide who have received 2008 New Innovator Awards ... are designed "to enable recipients to pursue exceptionally ... science." , The grants, which provide $1.5 million ... to Yuriy Kirichok, PhD, assistant professor of physiology, ...
... the Swiss Institute of,Bioinformatics in Berne, Switzerland, its director ... story". He said that he was,proud that as pioneers ... 25 working,groups was today able to announce the completion ... head of the SIB,s Swiss-Prot group said: "If human,DNA ...
... for People with Diabetes to Join,Him to Take the ... N.J., Sept. 24 Tony,Award-winning actor and Broadway star ... diabetes care, to launch Take the Stage,for Diabetes Awareness, ... diabetes about their condition. Since he was diagnosed,with type ...
... CHICAGO, Sept. 24 For the first ... a reproductive cancer, especially,ovarian and uterine (endometrial) ... a gynecologic oncologist. The 2008 State of ... to the Women of America,published by the ...
... Childhood ED ... Visits in US -, ROCKVILLE, ... a journey that parents dread making, but with,approximately 30 million children,s visits ... point in their lives. To help,parents and caregivers prepare, the Child Life ...
Cached Medicine News:Health News:AST to Address Human Resources Groups Nationwide to Encourage them to Adopt a Paid Leave Plan for Organ Donors 2Health News:2 UCSF scientists recognized for transformative research 2Health News:2 UCSF scientists recognized for transformative research 3Health News:Swiss Institute of Bioinformatics announces major breakthrough 2Health News:Swiss Institute of Bioinformatics announces major breakthrough 3Health News:Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment 2Health News:Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment 3Health News:Ovarian and Endometrial Cancer Patients Experience Improved Outcomes When Treated First by a Gynecologic Oncologist 2Health News:Ovarian and Endometrial Cancer Patients Experience Improved Outcomes When Treated First by a Gynecologic Oncologist 3Health News:Child Life Council Urges Parents to Think Ahead to Ease Child's Hospital Visit 2Health News:Child Life Council Urges Parents to Think Ahead to Ease Child's Hospital Visit 3Health News:Child Life Council Urges Parents to Think Ahead to Ease Child's Hospital Visit 4Health News:Child Life Council Urges Parents to Think Ahead to Ease Child's Hospital Visit 5Health News:Child Life Council Urges Parents to Think Ahead to Ease Child's Hospital Visit 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: